Lisata Therapeutics (LSTA) Stock: Buy, Sell, or Hold?
LSTA - Lisata Therapeutics, Inc. Common Stock
$1.63
-0.01 (-0.61%)
âŧ
5d:
-0.61%
30d:
+38.14%
90d:
-53.16%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When LSTA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: LSTA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: LSTA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: LSTA is currently trading at $1.63, which is considered slightly high relative to its 30-day fair value range of $1.13 to $1.72.
Technical Outlook: Technically, LSTA is in a strong downtrend. Immediate support is located at $1.23, while resistance sits at $2.00.
Market Sentiment: LSTA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.00 (+145.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LSTA is in a strong downtrend. Immediate support is located at $1.23, while resistance sits at $2.00.
Market Sentiment: LSTA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.00 (+145.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.13 -
$1.72
Company Quality Score
33/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
36.8%
All Signals
- BEARISH: Weak technical setup (15/100)
- BULLISH: Trading 145.4% below Wall St target ($4.00)
- WARNING: Composite score 33/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.13 -
$1.72
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.23
Resistance Level
$2.00
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.41
Wall Street Target
$4.00
(+145.4%)
Revenue Growth (YoY)
-90.0%
Share & Embed Analysis
Last updated: September 12, 2026 4:28 AM ET
Data refreshes hourly during market hours. Next update: 5:28 AM
Data refreshes hourly during market hours. Next update: 5:28 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LSTA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$370 | 43 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 48 HOLD |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$570 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$315 | 47 HOLD |
|
APLS
Apellis Pharmaceuticals âĻ |
BUY
22 analysts |
$41 | 50 HOLD |
